WO2009101968A1 - 抗adam-15抗体及びその利用 - Google Patents
抗adam-15抗体及びその利用 Download PDFInfo
- Publication number
- WO2009101968A1 WO2009101968A1 PCT/JP2009/052290 JP2009052290W WO2009101968A1 WO 2009101968 A1 WO2009101968 A1 WO 2009101968A1 JP 2009052290 W JP2009052290 W JP 2009052290W WO 2009101968 A1 WO2009101968 A1 WO 2009101968A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- adam
- fragment
- cell
- human
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/6416—Metalloendopeptidases (3.4.24)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
Definitions
- the present invention includes an antibody that specifically recognizes ADAM-15 (A Disintegrin And Metalloprotease), a fragment of the antibody (hereinafter collectively referred to as “antibody etc.”), a DNA encoding the antibody, etc., and the DNA
- the present invention relates to a recombinant vector, a cell transformed with the vector, a cell producing the antibody, a method for producing the antibody, a pharmaceutical composition containing the antibody, and a diagnostic agent containing the antibody.
- ADAM is a molecule containing a disintegrin domain containing many cysteine residues and a metalloprotease-like domain, and has attracted attention because it is a functional protein that can exert not only metalprotease activity but also adhesion molecule activity. .
- Many ADAMs have a transmembrane domain, are localized in the cell membrane, and play an extremely important role in molecular control on the cell surface. More than 30 types of ADAM family proteins have been identified, and the outside of the membrane has functions of cell adhesion, cell fusion, proteolysis, and intracellular signal transduction, so fertilization, neurogenesis, myoblast fusion, cytokines And other membrane proteins are thought to be involved in cleavage outside the membrane.
- ADAM family proteins are membrane-tethered proteins that are similar in structure to snake venom disintegrins, various biological processes involved in cell-cell and cell-matrix interactions (eg, fertilization, myogenesis, and Nerve development etc.).
- various biological processes involved in cell-cell and cell-matrix interactions eg, fertilization, myogenesis, and Nerve development etc..
- ADAM-13 is expressed in Xenopus laevis during development and is thought to play an important role in morphogenesis (see Non-Patent Document 4). At present, no mammal-derived ADAM-13 has been reported.
- ADAM-17 is known as a tumor necrosis factor (TNF) converting enzyme (a soluble TNF producing enzyme). Inhibitors of ADAM-17 have been energetically studied as preventive and / or therapeutic agents for diseases (inflammation, fever, circulatory system abnormalities, graft-versus-host reactions, autoimmune diseases, etc.) caused by abnormally increased TNF. ing.
- ADAM-17 itself and methods for screening for an inhibitor of ADAM-17 have already been disclosed (see Patent Documents 1 and 2).
- Non-patent Document 7 Since administration of a recombinant ADAM-15 disintegrin domain inhibits the growth of breast cancer cells, it is considered that the interaction between ADAM-15 and integrins is involved in the growth of cancer cells (Non-patent Document) 7).
- ADAM-15 is thought to be involved in the tissue repair process because of its increased expression due to rheumatoid arthritis and arteriosclerosis. ADAM-15 is considered to be involved in the tissue repair process in the heart because its expression is increased at the infarcted and non-infarcted sites early after the onset of myocardial infarction.
- the object of the present invention is to provide a therapeutic agent for cancer that focuses on a different viewpoint from the conventional development of anticancer agents, that is, cell-cell adhesion of cancer cells. That is, an object of the present invention is to provide a cancer therapeutic agent with reduced side effects, which suppresses the proliferation of cancer cells and cell-cell adhesion of cancer cells. Another object of the present invention is to provide an antibody that recognizes the disintegrin domain of ADAM-15 and can be used as an anticancer agent.
- a pharmaceutical composition comprising the antibody or fragment thereof according to any one of (1) to (12) above as an active ingredient.
- a diagnostic agent comprising the antibody or fragment thereof according to any one of (1) to (12) above.
- the diagnostic agent according to (22) above which is a diagnostic agent for a disease caused by cell proliferation, cell migration, cell-cell adhesion, or angiogenesis.
- an antibody or the like that binds to ADAM-15 and that does not recognize the RGD sequence in the disintegrin domain of ADAM-15, and binds to ADAM-15 An antibody or the like that does not recognize a loop region in the disintegrin domain of ADAM-15 is provided.
- the antibody of the present invention can be used as the antibody of the present invention, it may bind (or recognize) a substance other than ADAM-15, but preferably binds specifically to ADAM-15 (or Antibody) to be recognized).
- an antibody “specifically binds (or recognizes)” to a protein or a fragment thereof means that the antibody has a specific amino acid in these proteins or a fragment thereof rather than its affinity for other amino acid sequences. It means binding with substantially high affinity to the sequence.
- substantially high affinity means high affinity that allows the specific amino acid sequence to be detected separately from other amino acid sequences by a desired measuring apparatus or method.
- an antibody or the like that recognizes ADAM-15 such as an antibody that inhibits ADAM-15 and integrin ⁇ v ⁇ 3-dependent cell adhesion, and ADAM-15 and integrin ⁇ 9 ⁇ 1-dependent Antibodies that inhibit sexual cell adhesion are provided.
- ADAM-15 and integrin may be expressed on the same cell surface, or may be expressed on the surface of different cells, but are preferably expressed on the surface of different cells. It is a thing.
- the antibody of the present invention includes non-human animal antibodies, antibodies having the amino acid sequences of non-human animal antibodies and human-derived antibodies, and human antibodies.
- Non-human animal antibodies include, for example, antibodies such as mice, rats, hamsters, guinea pigs, rabbits, dogs, monkeys, sheep, goats, chickens and ducks, and preferably hybridomas can be produced. Animal antibodies, more preferably mouse antibodies. Examples of the antibody having the amino acid sequence of a non-human animal antibody and the amino acid sequence of a human-derived antibody include human chimeric antibodies and humanized antibodies.
- F (ab ′) 2 is an antibody fragment having an antigen-binding activity with a molecular weight of about 100,000 among fragments obtained by treating IgG with the proteolytic enzyme pepsin.
- Fab ′ is an antibody fragment having an antigen-binding activity having a molecular weight of about 50,000, which is obtained by cleaving a disulfide bond in the hinge region of F (ab ′).
- sdFv is a polypeptide having an antigen binding activity in which one VH and one VL are linked by a peptide linker.
- dsFv is a fragment having an antigen binding activity in which an amino acid residue substituted with a cysteine residue in VH and VL is bound via a disulfide bond.
- Diabody is a fragment obtained by dimerizing scFv.
- the diabody of the present invention may be monospecific or bispecific (multispecific antibody).
- the dimerized scFvs may be the same or different
- the peptide comprising a CDR sequence is a peptide comprising the amino acid sequence of at least one CDR selected from CDR1, CDR2 and CDR3 of the heavy chain variable region and CDR1, CDR2 and CDR3 of the light chain variable region. is there.
- the peptide containing a part of the anti-ADAM-15 antibody is more preferably a peptide containing the amino acid sequence of CDR3 of the heavy chain variable region and / or CDR3 of the light chain variable region.
- the representative heavy chain and light chain of the anti-ADAM-15 antibody of the present invention have the amino acid sequences of SEQ ID NO: 12 and SEQ ID NO: 14, respectively.
- the CDR1, CDR2, and CDR3 of the heavy chain variable region and the CDR1, CDR2, and CDR3 of the light chain variable region of representative examples of the anti-ADAM-15 antibody of the present invention are SEQ ID NO: 15, SEQ ID NO: 16, and SEQ ID NO: 17 and the amino acid sequences of SEQ ID NO: 18, SEQ ID NO: 19 and SEQ ID NO: 20.
- a disease associated with ADAM-15 is a disease caused by cell proliferation, cell migration, cell invasion, cell-cell adhesion, or angiogenesis, and examples of such diseases include cancer.
- ADAM-15 or a peptide having a part of ADAM-15 can be prepared by chemical synthesis using the Fmoc method or the Boc method.
- the C-terminal amino acid of ADAM-15 or a peptide having a part of ADAM-15 is immobilized on a polystyrene carrier, and 9-fluorenylmethyloxycarbonyl group (Fmoc group) or tert-butoxycarbonyl group (Boc group)
- Fmoc group 9-fluorenylmethyloxycarbonyl group
- Boc group tert-butoxycarbonyl group
- a peptide having a desired amino acid sequence can be obtained by combining the amino acid protected with ⁇ ⁇ ⁇ by reacting with a condensing agent such as diisopropylcarbodiimide (DIC) and repeating the washing and deprotection steps.
- DIC diisopropylcarbodiimide
- Administration of the immunogen to the animal can be performed, for example, by subcutaneous injection, intraperitoneal injection, intravenous injection, intradermal injection, intramuscular injection or footpad injection, preferably by subcutaneous injection or intraperitoneal injection. is there.
- the amount of the immunogen used is not particularly limited as long as it is an amount capable of producing an antibody, but is preferably 0.1 to 1000 ⁇ g, more preferably 1 to 500 ⁇ g, and still more preferably 10 to 100 ⁇ g.
- Immunization can be performed once or several times at appropriate intervals. Usually, immunization once every 1 to 6 weeks is performed 2 to 10 times in total, preferably immunization is performed once every 5 weeks, and more preferably once every 3 weeks. Immunization is performed a total of 3 times.
- the antibody-producing cells and myeloma cells obtained according to the above method are washed with a medium, PBS (Phosphate Buffered Saline), etc., and then 30 to 60% PEG (average molecular weight 1000 to 6000) or the like Suspension cells and myeloma cells are suspended at a mixing ratio of 1: 2 to 10: 1 (preferably 5: 1 to 10: 1) in an appropriate medium or buffer containing The reaction is carried out for about 30 seconds to 3 minutes under conditions of about 25 to 37 ° C. and pH 6 to 8 (Elsevier Publishing, 1988). After completion of the reaction, the PEG solution is removed and the suspension is resuspended in a culture medium and seeded in a cell well plate to continue the culture.
- PBS Phosphate Buffered Saline
- PEG average molecular weight 1000 to 6000
- Suspension cells and myeloma cells are suspended at a mixing ratio of 1: 2 to 10: 1 (preferably 5: 1 to 10
- the obtained antibody can be purified to homogeneity.
- Separation and purification methods used for ordinary proteins can be used for antibody separation and purification. For example, separating and purifying antibodies by appropriately selecting and combining chromatography columns such as affinity chromatography, filters, ultrafiltration, salting out, dialysis, SDS polyacrylamide gel electrophoresis, isoelectric focusing etc. (Antibodies: A Laboratory Manual. Ed Harlow and David Lane, Cold Spring Harbor Laboratory, 1988).
- Examples of the column used for affinity chromatography include a protein A column and a protein G column.
- HyperHD, POROS, Sepharose F. F. (Amersham Biosciences) can be mentioned.
- DNA encoding VH and VL of a non-human animal-derived monoclonal antibody can be obtained, for example, by the following method.
- MRNA is extracted from animal B cells producing the monoclonal antibody. Extraction of mRNA can be performed by methods well known to those skilled in the art. For example, guanidine-ultracentrifugation (Chirgwin, J. M. et al., Biochemistry, 18, 5294-5299, 1979), AGPC method (Chomczynski, P , Analytical Biochemistry, 162, 156-159, 1987), etc., and then purified by using an mRNA purification kit (Purification Kit) (Pharmacia, Takara Bio) or the like. .
- Purification Kit Purification Kit
- the human antibody FR has a high homology with the FR amino acid sequence of the human antibody in which the V region of the humanized antibody has a three-dimensional structure similar to the V region of the non-human animal-derived monoclonal antibody or the FR of the non-human animal-derived monoclonal antibody to be used.
- a mutation can be appropriately introduced into the amino acid sequence of FR of the obtained human antibody.
- DNA fragment of about 100 bp is bound using an enzyme such as ligase, PCR is performed using primers encoding the sequences at both ends of the designed DNA sequence encoding the V region of the humanized antibody, It can also be obtained by extracting a DNA fragment having a length of.
- DNA encoding the V region of a humanized antibody used for PCR can also be obtained by a method known as CDR grafting.
- the DNA encoding the V region of the humanized antibody to be used can also be obtained by incorporating a DNA encoding CDR into the V region DNA of the human antibody by site-directed mutagenesis.
- Site-specific mutations include, for example, Gene Taylor Site-Directed Mutagenesis System (Invitrogen), Transformer Site-Directed Mutagenesis Kit (Clontech), Site Directed It can be carried out by following the description of the kit using a Mutagenesis System (Takara Bio).
- enhancers and promoters used for expression of humanized antibodies include enhancers and promoters of immunoglobulin genes themselves or non-immunoglobulin enhancers and promoters.
- enhancers and promoters of immunoglobulin genes themselves or non-immunoglobulin enhancers and promoters.
- the mechanism for regulating the expression of immunoglobulin genes is common between mice and humans. Therefore, the mouse or human enhancer sequence present between the J gene and the C gene is used. Recombinant DNA can also be produced.
- the human antibody phage library allows human antibody Fab or scFv to be displayed on the surface as a fusion protein by introducing the VH gene and VL gene from the antibody gene pool having various sequences derived from human B cells into the phage gene.
- a phage library As such a human antibody phage library, naive / non-immune obtained by amplifying the VH gene and VL gene of a normal human antibody from peripheral blood lymphocytes by RT-PCR and making it into a library.
- V gene fragment A synthetic library (BioInvent; Crucell) in which a portion of an antigen-binding region such as a CDR3 region is replaced with an oligonucleotide encoding a random amino acid sequence of an appropriate length to form a library.
- Morphosys cancer, autoimmune disease Or infection patient or a library prepared from human lymphocytes inoculated with target antigen as a vaccine, may be mentioned immune library.
- a human antibody-producing transgenic mouse is a mouse in which an Ig gene of a human antibody is introduced into a mouse in which an endogenous immunoglobulin (Ig) gene is knocked out.
- a human antibody-producing transgenic mouse can be obtained, for example, by the following method.
- colcemid a spindle formation inhibitor
- microcells which are structures in which one to several chromosomes are enveloped in the nuclear membrane, are formed.
- Microcells isolated in the presence of cytochalasin B are fused with chromosome recipient cells (mouse ES cells) with polyethylene glycol to produce microcell hybrid ES cells, which are injected into mouse embryos.
- the antibody fragment of the present invention (F (ab ′) 2 , Fab ′, Fab, scFv, dsFv or a polymer thereof, diabody, or a peptide containing CDR) should be prepared by the following method. Can do.
- the Fab ′ fragment of the present invention can be obtained by treating F (ab ′) 2 that binds to ADAM-15 of the present invention obtained by the above-described method with dithiothreitol as a reducing agent.
- the Fab ′ fragment of the present invention can be obtained by inserting a DNA encoding Fab ′ of an antibody that binds to ADAM-15 of the present invention into an expression vector, introducing the vector into a host cell, and expressing it. it can.
- the Fab fragment of the present invention is obtained by treating an antibody that binds to ADAM-15 of the present invention with the proteolytic enzyme papain and cleaving it at the 224th amino acid residue of the H chain, so that about half of the N-terminal side of the H chain is obtained.
- the Fab fragment of the present invention can be obtained by inserting DNA encoding the Fab of the antibody that binds to ADAM-15 of the present invention into an expression vector, introducing the vector into a host cell, and expressing it.
- the scFv of the present invention obtains cDNAs encoding the VH and VL of the antibody that binds to ADAM-15 of the present invention, inserts a DNA encoding a linker sequence between these genes, and converts the DNA encoding the scFv into It can be obtained by constructing, inserting the DNA into an expression vector, introducing the vector into a host cell and expressing it.
- the length of the linker is not particularly limited as long as VH and VL can associate with each other, but is preferably 10 to 20 residues, and more preferably 15 residues.
- the linker sequence is not particularly limited as long as it does not inhibit the folding of the polypeptide chains of the two domains of VH and VL, but is preferably a linker consisting of glycine and / or serine, more preferably , GGGGS (G: glycine, S: serine) or a repetitive sequence thereof.
- the diabody of the present invention is constructed so that the amino acid sequence of the linker is 8 residues or less (preferably 5 residues) in the above-mentioned scFv-encoding DNA, the DNA is inserted into an expression vector, It can be obtained by introducing it into a host cell and expressing it.
- Bispecific diabody can be obtained by preparing scFv by combining VH and VL DNAs of two different types of scFv.
- the peptide containing CDR of the present invention constructs a DNA encoding the amino acid sequence of CDR of antibody VH or VL that binds to ADAM-15 of the present invention, inserts the DNA into an expression vector, and uses the vector as a host. It can be obtained by introducing into a cell and expressing it.
- the antibody that binds to ADAM-15 of the present invention can be obtained by the method described above.
- the antibody can be obtained by selecting an antibody that recognizes a desired epitope from among the antibodies.
- an antibody or the like that recognizes ADAM-15 of the present invention is obtained by administering a peptide having a desired epitope sequence (preferably, a disintegrin domain sequence) as an antigen in the above-described method for producing an anti-ADAM-15 antibody. be able to.
- An antibody that recognizes the disintegrin domain of ADAM-15 can be obtained by selection by a method well known to those skilled in the art. For example, for an antibody that recognizes the ADAM-15 disintegrin domain, the binding activity between the ADAM-15 disintegrin domain peptide and the antibody obtained by the above method is measured, and an antibody having a high binding activity is selected. Can be obtained.
- the binding constant (K a ) in the binding between the anti-ADAM-15 antibody of the present invention and the disintegrin domain of ADAM-15 is, for example, at least 10 7 M ⁇ 1 , preferably at least 10 8 M ⁇ 1. And more preferably at least 10 9 M ⁇ 1 .
- an antibody that recognizes the ADAM-15 disintegrin domain and does not recognize the RGD sequence in the ADAM-15 disintegrin domain such as an antibody that recognizes the ADAM-15 disintegrin domain obtained by the above method, etc.
- an antibody that does not recognize the RGD sequence in the disintegrin domain of ADAM-15 can be obtained by selecting by a method well known to those skilled in the art.
- an antibody that recognizes the ADAM-15 disintegrin domain and does not recognize the RGD sequence in the ADAM-15 disintegrin domain is an ADAM-15 disintegrin domain among the amino acids constituting ADAM-15.
- the binding between the obtained antibody and ADAM-15 or a fragment thereof or a mutant thereof can be measured by methods well known to those skilled in the art. Examples of such methods include Western Blotting and X-ray crystal analysis, as well as Biacore System (Biacore).
- ADAM-15 and integrin ⁇ 9 ⁇ 1-dependent cell adhesion Whether the obtained antibody inhibits ADAM-15 and integrin ⁇ v ⁇ 3-dependent cell adhesion can be determined by, for example, ADAM- in the presence / absence of the obtained antibody. It can be examined by comparing the binding of integrin ⁇ 9 ⁇ 1-expressing cells to a plate on which 15 recombinant proteins are immobilized. By measuring the binding of integrin ⁇ 9 ⁇ 1-expressing cells to the plate on which the ADAM-15 recombinant protein is immobilized in the presence / absence of an anti-integrin ⁇ 9 ⁇ 1 antibody as a control, Whether or not it is ⁇ 9 ⁇ 1-dependent cell adhesion can be known.
- composition Since the obtained antibody and the like can block intracellular signal transmission of information by inhibiting the binding between ADAM-15 and integrin, it should be used as a therapeutic agent for diseases involving such signals. Can do.
- the target disease such as the antibody of the present invention can be determined. Can be found.
- the antibody or the like obtained by the above method can be purified as necessary and then formulated according to a conventional method and used as a preventive and / or therapeutic agent for various diseases.
- the administration site include oral administration, buccal administration, intratracheal administration, subcutaneous administration, intramuscular administration, and intravascular (intravenous) administration.
- the antibody of the present invention may be administered alone, or a pharmaceutically and pharmacologically acceptable carrier (refer to “Pharmaceutical Additives Encyclopedia” Yakuji Nippo, “HandbookHandofHandPharmaceutical Excipients” APhA Publications), diluted It may be administered as a pharmaceutical composition using an agent or additive.
- the pharmaceutical composition of the present invention is provided as a dosage form suitable for parenteral administration or oral administration.
- compositions for parenteral administration include injections, nasal drops, suppositories, patches, ointments and the like.
- the injection includes dosage forms such as intravenous injection, subcutaneous injection, intradermal injection, intramuscular injection, and drip injection.
- Such an injection can be prepared according to a known method, for example, by dissolving, suspending or emulsifying the above-mentioned antibody or the like in a sterile aqueous or oily liquid usually used for injection.
- the prepared injection solution is usually filled in appropriate ampules, vials, and syringes.
- a suppository used for rectal administration is prepared by mixing the above-mentioned antibody into a usual nasal base or suppository base.
- a lyophilized preparation can be prepared by adding an appropriate excipient to the above antibody, and dissolved in water for injection or physiological saline at the time of use to obtain an injection solution.
- oral administration of a protein such as an antibody is difficult because it is degraded by the digestive tract, but there is a possibility of oral administration depending on the ingenuity of the antibody fragment or modified antibody fragment and the dosage form.
- Examples of the preparation for oral administration include capsules, tablets, syrups, granules and the like.
- the diagnostic agent comprises the antibody of the present invention is a diagnostic agent for inflammatory diseases such as rheumatoid arthritis, hepatitis, bronchial asthma, fibrosis, diabetes, cancer metastasis, arteriosclerosis, multiple sclerosis, granulomas, and organ transplantation.
- the diagnostic agent of the present invention can be based on a known method using an antibody molecule. Examples of such methods include ELISA (Catty, Raykundalia, 1989), radioimmunoassay (Catty, Murphy, 1989), immunohistochemical method (Heider et al., 1993), immunometric method, or Western blot. Can be mentioned.
- tissue sample or fluid collected from a subject as a biopsy can be used as a sample of the diagnostic agent of the present invention.
- the biopsy used is not particularly limited as long as it is a target of ADAM-15 immunological measurement.
- Analysis with the diagnostic agent of the present invention can be performed qualitatively, quantitatively or semi-quantitatively.
- various labeling for example, biotin labeling, FITC labeling, APC labeling
- a label is preferably a biotin label using Biotin® Labeling® Kit (Dojin Chemical).
- ADAM-15 can be quantified with high sensitivity by using the antibody of the present invention. Furthermore, by using the ADAM-15 quantification method in vivo using the antibody of the present invention, the prognosis, presence / absence, extent, prognosis, effect of pharmaceuticals, etc. of various diseases related to ADAM-15 are diagnosed. be able to. For example, if an increase or decrease in the concentration of ADAM-15 is detected, it can be diagnosed that ADAM-15 is likely to be a disease associated with it, such as an inflammatory disease, or likely to be affected in the future.
- the antibodies of the present invention can be used to prepare an antibody column used for purifying ADAM-15, detect ADAM-15 contained in each fraction during purification, and the behavior of ADAM-15 in test cells. It can be used for analysis.
- the following culture media were used as the culture media for cell culture.
- D-MEM Ham's F-12 medium containing 5% FCS (Wako); culturing CHO cells constitutively expressed human ⁇ 9 integrin (ha9 / CHO), 600 ⁇ g / ml G418
- NRC-12 human renal cancer cell line
- MDA-MB-435S: 435S human breast cancer cell line
- IBL human renal cancer cell line
- D-MEM (Wako) medium containing 10% FCS when culturing COS-7 cells were cultivating human renal cancer cell line (NRC-12) and human breast cancer cell line (MDA-MB-435S: 435S).
- IBL human renal cancer cell line
- Example 1 Production of human ⁇ 9 integrin constant expression strain
- the human ⁇ 9 integrin gene was cloned from total RNA extracted from G361 cells by PCR using cDNA synthesized using ReverTraAce (TOYOBO) as a template. Cloning of the human ⁇ 9 integrin gene was performed by dividing it into 5 ′ and 3 ′ fragments and using the following primers.
- the PCR product of the human ⁇ 9 integrin gene 5 ′ fragment was treated with HindIII and PstI, and the PCR product of the 3 ′ fragment was treated with restriction enzyme at 37 ° C. for 1 hour using EcoRV, and each was treated with pBluescript SK (+) vector (Stratagene
- the plasmid was extracted (5 ′ side fragment: ⁇ 9F / pBS, 3 ′ side fragment: ⁇ 9R / pBS).
- Each plasmid was treated with restriction enzymes using AccIII and XbaI at 37 ° C. for 1 hour.
- the ⁇ 9R fragment was purified and introduced into the AccIII and XbaI sites of ⁇ 9F / pBS.
- This plasmid was digested with HindIII and XbaI to cut out the insert site and introduced into a pcDNA3.1 (+) vector (Invitrogen) ( ⁇ 9 / pcDNA3.1 (+)).
- ⁇ 9 / pcDNA3.1 (+) was introduced into CHO-K1 cells using Lipofectamine-2000 (Invitrogen), and 10% FCS (SIGMA-Aedrich) adjusted so that Geneticin G418 (Invitrogen) was 600 ⁇ g / ml Drug-resistant cells were selected by using DMEM Ham'sF-12 (WAKO). The selected cells were screened by flow cytometry, and CHO-K1 cells that constantly express human ⁇ 9 integrin were established by repeating limiting dilution (hereinafter referred to as “h ⁇ 9 / CHO cells”).
- Example 2 Production of human ADAM-15 disintegrin domain / pGEX-6P-1 The DNA strand of human ADAM-15 disintegrin domain was replicated by PCR. HUVEC cDNA 1 ⁇ L as template, 0.5 ⁇ L 100 ⁇ M sense primer and 100 ⁇ M antisense primer, 8 ⁇ L 2.5mM dNTP mix, 0.5 ⁇ L EX-Tag polymerase (2.5U / 100 ⁇ L: Takara), 10 ⁇ L 10 ⁇ PCR buffer was added to 79.5 ⁇ L of ultrapure water to prepare a PCR reaction solution.
- PCR reaction was performed in 94 ° C for 5 minutes in 1 cycle, 94 ° C for 1 minute, 55 ° C for 1 minute, 72 ° C for 1 minute in 35 cycles, and 72 ° C for 5 minutes in 1 cycle.
- the used primers are as follows.
- Antisense primer 5'-CATGCACACAGCTTGCCC-3 '(SEQ ID NO: 6)
- a BamHI / XhoI site was added to the DNA strand of the human ADAM-15 disintegrin domain.
- PCR reaction was performed in 94 ° C for 5 minutes for 1 cycle, 94 ° C for 1 minute, 53 ° C for 1 minute, 72 ° C for 30 seconds for 35 cycles, and 72 ° C for 5 minutes for 1 cycle.
- the used primers are as follows.
- Sense primer 5'-AAGGATCCGCTGCTTTCTGCGGA-3 '(SEQ ID NO: 7)
- Antisense primer 5'-ATTCTCGAGATCCCCTAGGCTGACAT-3 '(SEQ ID NO: 8)
- the PCR product was electrophoresed on a 2% agarose gel, the target band was excised, and purified using a DNA purification kit (Wizard SV SV Gel and PCR Clean-up System: PROMEGA).
- the prepared DNA strand was inserted into a pGEX-6P-1 vector treated with a restriction enzyme with BamHIho / XhoI. This was transformed into JM-109 and replicated. Then, it refine
- Example 3 Preparation of human ADAM-15 disintegrin domain-GST protein Human ADAM-15 disintegrin domain / pGEX-6P-1 prepared in Example 2 was transformed into JM-109, and ampicillin (SIGMA- GST fusion protein expression was induced by adding 200 ⁇ M IPTG (Amersham Bioscience) in the logarithmic growth phase. After recovering E. coli, the protein was extracted by suspending in NETN-150 buffer (50 mM Tris pH 7.2, 1 mM EDTA, 150 mM NaCl, 0.5% NP-40) and applying sonication.
- NETN-150 buffer 50 mM Tris pH 7.2, 1 mM EDTA, 150 mM NaCl, 0.5% NP-40
- Sense primer 5'-CAGTGTCCTACCAGAGCTGCTTGTGACTTGCCTG-3 '(SEQ ID NO: 9)
- Antisense primer 5'-CAGGCAAGTCACAAGCAGCTCTGGTAGGACGACACTG-3 (SEQ ID NO: 10)
- Example 5 Preparation of anti-human ADAM-15 disintegrin domain monoclonal antibody (8F7)
- Human ADAM-15 disintegrin domain-GST protein prepared in Example 3 was treated with BALB / c mice (female, 7 weeks old: SAMKYO).
- LABO SERVICE CORPORATION was immunized 4 times in total. The first time, 100 ⁇ g of protein was emulsified with complete Freund's adjuvant (SIGMA), and then 50 ⁇ g of protein was emulsified with incomplete Freund's adjuvant (SIGMA) to immunize mice. After four immunizations, blood was collected from the mice, and antibody titers were measured by ELISA using the serum. Thereafter, 50 ⁇ g of protein was dissolved in PBS and boosted.
- SIGMA complete Freund's adjuvant
- SIGMA incomplete Freund's adjuvant
- the spleen was removed from the mouse, and the spleen cells and X63-Ag8-653 myeloma cells were fused with polyethylene glycol (IBL). Thereafter, the cells were selectively cultured in HAT medium, and after hybridoma colony formation was observed, the culture supernatant was used to screen for binding to an antigen protein by ELISA.
- human ADAM-15 disintegrin domain-GST protein as an antigen was immobilized on a solid phase of 50 ng in each well, and a hybridoma culture supernatant diluted 2-fold as a primary antibody was used. Single clones were obtained by limiting dilution of positive colonies twice.
- the culture supernatant of the obtained clone was purified with an antigen column, and a monoclonal antibody (clone name: 8F7, hereinafter referred to as “8F7”) was established.
- the hybridoma cell producing this monoclonal antibody has the accession number FERM ABP-10950 (accession number FERM BP-10950), 1st East 1st Street, Tsukuba City, Ibaraki Prefecture, Central 6th (Postal Code 305-8586), Independent Administrative Institution Sangyo Deposited at the Research Center for Biological Biology on February 13, 2008.
- the antigen specificity of the prepared 8F7 was confirmed by ELISA.
- GST, human ADAM-15 disintegrin domain-GST protein, human ADAM-15 disintegrin domain loop region-GST protein, human ADAM-15 disintegrin domain protein, human ADAM-15 disintegrin domain protein (RAA) Substrate) and mouse osteopontin N-half-GST protein were serially diluted from 10 ⁇ g / ml and immobilized on a solid phase, and 8F7 adjusted to 0.1 ⁇ g / ml was used as the primary antibody.
- the results are shown in FIG. In the examination by ELISA method, although it shows a cross-reaction with GST, the reaction is weak.
- loop region a loop region that is considered necessary for adhesion to integrin.
- COS-7 cells were cultured to 80% confluence on a 6 cm culture plate, and 3 ml of OPTI-MEM medium (GIBCO) supplemented with 4 ⁇ g of human ADAM-15 / pcDNA 3.1 (+) and 20 ⁇ L of Lipofectamine-2000 (Invitrogen). And cultured at 37 ° C. for 6 hours. Thereafter, the medium was replaced with 3 ml of DMEM medium containing 10% FCS and cultured at 37 ° C. for 48 hours to obtain human ADAM-15-introduced COS-7 cells.
- OPTI-MEM medium Gibco-MEM medium
- FIG. 8F7 showed a high binding activity to the ADAM-15 disintegrin domain independent of the RGD sequence.
- 23G9 has a lower binding activity to human ADAM-15 disintegrin domain (dd) and human ADAM-15 disintegrin domain-GST protein (dd-GST) than ADG-15 It was shown that it did not recognize the disintegrin domain. Therefore, it was suggested that 8F7 has various functions by inhibiting ADAM-15 that has not been found so far, by binding to a binding site different from the anti-ADAM-15 antibody known so far. .
- the h ⁇ 9 / CHO cells or non-gene-transferred CHO-K1 cells prepared in Example 1 were made 1 ⁇ 10 5 cells / ml with 0.25% BSA-containing medium (D-MEM Ham'sF-12). After preparation, 200 ⁇ L was added to each well and incubated at 37 ° C. for 1 hour to adhere to the protein immobilized on the solid phase. Thereafter, the cells were washed with PBS preliminarily warmed to 37 ° C. to remove non-adherent cells. 50 ⁇ L of crystal violet was added to each well and incubated at room temperature for 30 minutes to fix and stain the cells. After washing with tap water, 100 ⁇ L of 20% aqueous acetic acid was added to each well to lyse the cells, and the absorbance at 590 nm was measured with a plate reader.
- BSA-containing medium D-MEM Ham'sF-12
- a human ADAM-15 disintegrin domain recombinant protein (prepared to 2.5 ⁇ g / ml) from which GST was removed was immobilized by the same method as in the cell adhesion test, and a blocking reaction was performed.
- 8F7 diluted serially to a concentration of 0 to 10 ⁇ g / ml was added to the immobilized protein. Incubate at 37 ° C. for 20 minutes to allow the cells to adhere. Thereafter, cell adhesion was examined by the same method as in the cell adhesion test.
- dd Human ADAM-15 disintegrin domain
- RAA substitute human ADAM-15 disintegrin domain
- FIG. 4A The result of the adhesion test for “dd-RAA” is shown in FIG. 4A.
- h ⁇ 9 / CHO cells show almost the same cell adhesion activity when dd-RAA is immobilized on solid phase, so that the interaction between h ⁇ 9 / CHO cells and dd is , Dd was shown to be independent of the RGD sequence.
- CHO-K1 cells endogenously express integrins that bind to RGD sequences such as ⁇ v ⁇ 1 integrin, ⁇ v ⁇ 5 integrin, ⁇ 5 ⁇ 1 integrin (Eto, K., Huet, C., Tarui, T., Kupriyanov, S). ., Liu, H. Z., Puzon-McLaughlin, W., Zhang, X.
- adhesion of h ⁇ 9 / CHO to the ADAM-15 disintegrin domain-immobilized surface is adhesion via ⁇ 9 integrin.
- Adhesion of h ⁇ 9 / CHO to the ADAM-15 disintegrin domain immobilized surface does not decrease even with dd-RAA. Therefore, adhesion via ⁇ 9 integrin and ADAM-15 disintegrin domain is ADAM-15 disintegrin domain.
- the RGD sequence is considered to be independent.
- FIG. 4B shows the results of an inhibition test of adhesion of the h ⁇ 9 / CHO cells to the d.d. and d.d.-RAA solid-phased surfaces by the 8F7 antibody.
- the 8F7 antibody inhibited h ⁇ 9 / CHO cell adhesion to d.d. and d.d.-RAA in a concentration-dependent manner. From the above results, it is considered that the adhesion of h ⁇ 9 / CHO cells to the dd and dd-RAA solid-phased surfaces is adhesion via ⁇ 9 integrin. Therefore, 8F7 is composed of human ADAM-15 and human ⁇ 9 ⁇ 1 integrin. It was confirmed that the interaction was suppressed.
- Example 9 Cell Adhesion and Cell Adhesion Inhibition Test Using Human Renal Cancer Cell Line NRC-12 Cells
- dd of human renal cancer cell line NRC-12 cells was immobilized.
- the results are shown in FIG.
- the human renal cancer cell line NRC-12 cells adhered to ADAM-15 d.d. and -synthetic peptide GRGDS-BSA in an RGD sequence-dependent manner.
- the 8F7 antibody inhibited the adhesion of human renal cancer cell line NRC-12 cells to the d.d. solid-phased surface in a concentration-dependent manner.
- human renal cancer cell line NRC-12 cells do not express ⁇ 9 ⁇ 1 integrin but express integrins that bind to RGD sequences ( ⁇ v ⁇ 3 integrin, ⁇ 5 ⁇ 1 integrin), so 8F7 is an RGD of dd and integrin. It is thought to suppress cell adhesion due to dependent interactions.
- Example 10 Expression of integrin in human breast cancer cell line 435S Expression of ADAM-15 and integrin in human breast cancer cell line 435S (MDA-MB-435S) was confirmed by flow cytometry. Flow cytometry was performed according to the method described in Example 7.
- results are shown in FIG.
- human breast cancer cell line 435S the expression of ADAM-15, ⁇ v ⁇ 3 integrin, ⁇ 5 ⁇ 1 integrin and ⁇ 9 ⁇ 1 integrin was examined, and it was confirmed that all molecules were expressed. However, there was a difference in the expression level, and ⁇ v ⁇ 3 integrin and ⁇ 5 ⁇ 1 integrin had higher expression levels than ⁇ 9 ⁇ 1 integrin.
- dd, dd-RAA a protein in which the RGD sequence of the recombinant protein (hTNfn3) of the third fibronectin typeIII domain (hTNfn3) present in the human tenascin C molecule is replaced with RAA (hTNfn3 (RAA)), or GRGDS-BSA in PBS Prepared at 0-5 ⁇ g / mL, added 50 ⁇ L to each well of a 96-well plate, and incubated at 37 ° C. for 1 hour to immobilize. Thereafter, 200 ⁇ L of 0.5% BSA / PBS was added to each well and incubated at room temperature for 1 hour to perform a blocking reaction.
- RAA hTNfn3
- human breast cancer cell line 435S cells are adjusted to 1 ⁇ 10 5 cells / ml with 0.25% BSA-containing medium (TIL), 200 ⁇ L is added to each well, and incubated at 37 ° C. for 1 hour to solidify. Adhered to the phased proteins. Thereafter, the cells were washed with PBS preliminarily warmed to 37 ° C. to remove non-adherent cells. 50 ⁇ L of crystal violet was added to each well and incubated at room temperature for 30 minutes to fix and stain the cells. After washing with tap water, 100 ⁇ L of 20% aqueous acetic acid was added to each well to lyse the cells, and the absorbance at 590 nm was measured with a plate reader.
- TIL BSA-containing medium
- FIG. 8A shows the results of a cell adhesion test using the human breast cancer cell line 435S cells.
- the human breast cancer cell line 435S adhered to d.d. or d.d.-RAA, but the adhesion rate was low.
- integrins are activated by divalent ions (Mn, Mg, Ca ions, etc.).
- divalent ions Mn, Mg, Ca ions, etc.
- integrin activation by divalent ions is required for adhesion between ADAM-15 and integrin (Eto, K et al. RGD-independent binding of integrin alpha9beta1 to the ADAM-12 and- 15 disintegrin domains mediate cell-cell interaction. J Biol. Chem. 275: 34922-34930,2000).
- integrin was activated by using Mn ions in the cell adhesion test using the above-described human breast cancer cell line 435S cells.
- Results are shown in FIG. 8B. Addition of Mn ions increased the adhesion rate of human breast cancer cell line 435S cells to d.d. or d.d.-RAA.
- Example 12 Cell adhesion inhibition test using human breast cancer cell line 435S cells
- integrin was activated by using Mn ions.
- dd or dd-RAA prepared to 6.25 ⁇ g / ml
- a blocking reaction was performed in the same manner as in the cell adhesion test.
- 8F7 was added to the protein immobilized on the solid phase.
- RGD sequence containing the RGD sequence was bound via an RGD receptor such as ⁇ v ⁇ 3 integrin, and binding via ⁇ 9 ⁇ 1 integrin was not observed. On the other hand, binding via d9d1 integrin was observed for d.d.-RAA containing no RGD sequence.
- Example 13 Cell Proliferation Test Human breast cancer cell line 435S cells (MDA-MB-435S: 435S) were adjusted to 2 ⁇ 10 4 / ml with 10% FCS-containing TIL medium, and 100 ⁇ L per well of a 96-well plate. Then, after overnight culture at 37 ° C., the medium was replaced with FCS-free TIL medium, and similarly cultured overnight. Remove the medium and add 100 ⁇ L of antibody (8F7 prepared in Example 5 or anti-human ⁇ v ⁇ 3 integrin antibody LM-609 (chemicon)) adjusted to 20 ⁇ g / ml with 5% FCS-containing TIL medium to each well. 10 ⁇ L of cell counting kit-8 (DOUJINDO) was added to each well.
- DOUJINDO cell counting kit-8
- Example 14 Cell Invasion Inhibition Test Using Human Breast Cancer Cell Line 435S Cells A cell infiltration test was performed to examine the effect of 8F7 on cell infiltration. The cell infiltration test was performed using a Matrigel invasion chamber (BD). 500 ml of serum-free TIL medium (Immunobiology Laboratories) was added to each well and insert, and the insert was immersed in the well. Matrigel was hydrated by incubation for 2 hours at 37 ° C. Thereafter, the medium in the insert was removed by suction and immersed in another well to which 750 ml of a chemoattractant was added. As the chemoattractant, the culture supernatant of the human fibroblastoma cell line HT-1080 cell line was used.
- BD Matrigel invasion chamber
- the results are shown in FIG.
- the ratio of the number of infiltrating cells obtained in the antibody addition group was calculated based on the number of infiltrating cells when no antibody was added.
- these experiments were performed in triplicate and Student's t-test was performed.
- the control antibody was added, the number of infiltrating cells remained almost unchanged, but when the 8F7 antibody was added, the ratio of infiltrating cells decreased to about 30%. It was confirmed that it has an inhibitory effect.
- Example 15 Amino acid sequence analysis of antibody Hybridoma cells were extracted from RNA using illustra Quickprep Micro mRNA Purification Kit (GE Healthcare Biosigns), and were added to the SuprScriptFirst-strand cDNA for RT-PCR kit (Invitrogen). Thus, cDNA was prepared. PCR is performed using a heavy primer amplification kit (Amersham Biosciences) and a Lightprimer amplification kit (Amersham Biosciences) to extend the heavy chain of the antibody and the light chain of the antibody, and then the heavy chain.
- a heavy primer amplification kit Amersham Biosciences
- a Lightprimer amplification kit Amersham Biosciences
- the PCR product was incorporated into a pTA vector (Toyobo Co., Ltd.), and the light chain PCR product was incorporated into Mighty Cloning Kit ⁇ Blunt End> (Takara Bio) to determine the cDNA sequence and amino acid sequence.
- the CDR region was determined using the Kabat numbering system.
- Primer is prepared based on the cDNA sequence obtained by the above method, and 5′RACE and 3′RACE of antibody heavy chain and antibody light chain are performed using GeneRacer®Kit (Invitrogen), and the full length of the antibody gene Analysis was performed.
- GeneRacer®Kit Invitrogen
- the amino acid sequences of the heavy chain, light chain, and CDR regions were as follows (see also FIGS. 12 and 13).
- the anti-ADAM-15 antibody of the present invention exhibits an excellent ADAM-15 function inhibitory action, it is used as a therapeutic or prophylactic agent for diseases caused by cell proliferation, cell migration, cell infiltration, cell-cell adhesion, and angiogenesis. Can be used.
- the antibody of the present invention is used for cancer (eg, cancer cell proliferation, metastasis), inflammatory disease (eg, rheumatoid arthritis, osteoarthritis, hepatitis, bronchial asthma, cotton fibrosis, diabetes, arteriosclerosis, multiple Sclerosis, inflammatory bowel disease (ulcerative colitis, Crohn's disease, etc.), infection (eg, hepatitis), autoimmune disease (eg, systemic lupus erythematosus, polymyositis, autoimmune thyroid disease, between tubules) It can be used as a therapeutic or prophylactic agent for interstitial nephritis, myasthenia gravis) and bone diseases (for example, osteoporosis).
- the antibody of the present invention can pathologically detect ADAM-15 expression in cells and tissues, it can be used as a diagnostic agent for the above-mentioned various diseases.
- dd-GST human ADAM-15 disintegrin domain-GST protein
- dd-GST human ADAM-15 disintegrin domain loop region-GST protein
- dd human ADAM-15 disintegrin domain protein
- ROA substitute human ADAM -15 disintegrin domain protein
- mOPN N-half-GST mouse osteopontin N-half-GST protein
- the result of having measured the RGD sequence-independent cell adhesion inhibitory activity of 8F7 is represented.
- A shows the results of measuring cell adhesion of CHO-K1 and h ⁇ 9 / CHO to the hADAM-15 disintegrin domain.
- the vertical axis represents the absorbance at 590 nm
- the horizontal axis represents the concentration of the immobilized polypeptide.
- B shows the results of measuring the inhibitory activity of 8F7 on cell adhesion of h ⁇ 9 / CHO to the hADAM-15 disintegrin domain.
- the vertical axis represents the absorbance at 590 nm
- the horizontal axis represents the concentration of the immobilized polypeptide.
- the result of having measured the expression of the integrin in the human renal cancer cell line NRC-12 by flow cytometry is shown.
- ⁇ 9 ⁇ 1 integrin was detected using Y9A2
- ⁇ v ⁇ 3 integrin was detected using LM609
- ⁇ 5 ⁇ 1 integrin was detected using JBS5.
- the result of having measured the RGD sequence-dependent cell adhesion inhibitory activity of 8F7 is represented.
- A represents the result of examining cell adhesion between NRC-12 and hADAM-15 disintegrin domain.
- the vertical axis represents the absorbance at 590 nm
- the horizontal axis represents the concentration of the immobilized polypeptide.
- FIG. B shows the results of measuring the inhibitory activity of 8F7 on cell adhesion of NRC-12 to the hADAM-15 disintegrin domain.
- the vertical axis represents the absorbance at 590 nm
- the horizontal axis represents the concentration of the immobilized polypeptide.
- 3 shows the results of measuring integrin expression in a human breast cancer cell line (MDA-MB-435S) by flow cytometry. ⁇ 9 ⁇ 1 integrin was detected using Y9A2, ⁇ v ⁇ 3 integrin was detected using LM609, and ⁇ 5 ⁇ 1 integrin was detected using JBS5. The result of a cell adhesion test using a human breast cancer cell line (MDA-MB-435S) is shown.
- A shows the results of measuring cell adhesion to the hADAM-15 disintegrin domain.
- the vertical axis represents the absorbance at 590 nm
- the horizontal axis represents the concentration of the immobilized polypeptide.
- B shows the results of measuring cell adhesion to the hADAM-15 disintegrin domain in the presence of Mn ions.
- the vertical axis represents the absorbance at 590 nm
- the horizontal axis represents the concentration of the immobilized polypeptide.
- the results of a cell adhesion inhibition test using a human breast cancer cell line (MDA-MB-435S) are shown.
- A shows the result of inhibition of adhesion of human breast cancer cell line (MDA-MB-435S) to the disintegrin domain of ADAM-15 with 8F7.
- B shows the results of inhibition of adhesion of human breast cancer cell line (MDA-MB-435S) to ADAM-15 disintegrin domain (RAA substitute) with 8F7.
- C shows the result of inhibition of adhesion of human breast cancer cell line (MDA-MB-435S) to ADAM-15 to the disintegrin domain with Y9A2 or LM609.
- D shows the result of inhibition of adhesion of the human breast cancer cell line (MDA-MB-435S) to the ADAM-15 disintegrin domain (RAA substitute) with Y9A2 or LM609.
- the vertical axis represents the cell adhesion rate when the non-antibody addition is 100%
- the horizontal axis represents the administered antibody.
- 3 shows the results of measuring the ADAM-15 function in cell growth of human breast cancer cell line (MDA-MB-435S) and the inhibitory activity of the function by 8F7. Each antibody was added at 20 ⁇ g / mL.
- the vertical axis represents the cell growth rate after 48 hours.
- the result of the cell infiltration inhibition test using human breast cancer cell line 435S sputum cells is shown.
- the base sequence and amino acid sequence of an anti-human ADAM-15 antibody (8F7) heavy chain are shown. The amino acid sequence is indicated by a single letter code.
- the signal sequence is italic, and the amino acid residue (Q) corresponding to the N-terminus of the antibody is indicated by a double underline.
- the CDR estimated by Kabat Kanumbering system is underlined.
- the amino acid residue (A) at the boundary between the variable region and the constant region of the antibody is shown in bold underline.
- the base sequence and amino acid sequence of an anti-human ADAM-15 antibody (8F7) light chain are shown.
- the amino acid sequence is indicated by a single letter code.
- the signal sequence is italic, and the amino acid residue (D) corresponding to the N-terminus of the antibody is indicated by a double underline.
- the CDR estimated by Kabat Kanumbering system is underlined.
- the amino acid residue (R) at the boundary between the variable region and the constant region of the antibody is shown in bold underline.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
(2)ADAM-15のディスインテグリンドメインドメインを認識し、かつ、ADAM-15のディスインテグリンドメイン内のループ領域を認識しない抗体またはその断片。
(3)上記(1)又は(2)に記載の抗体またはその断片であって、ADAM-15及びインテグリンαvβ3依存性細胞接着を阻害する抗体またはその断片。
(4)上記(1)~(3)のいずれか1項に記載の抗体またはその断片であって、ADAM-15及びインテグリンα9β1依存性細胞接着を阻害する抗体またはその断片。
(5)上記(1)~(4)のいずれか1項に記載の抗体またはその断片であって、癌細胞の増殖を抑制することを特徴とする抗体またはその断片。
(6)上記抗体が、モノクローナル抗体である、上記(1)~(5)のいずれか1項に記載の抗体またはその断片。
(7)上記抗体が、配列番号12のアミノ酸配列を有する重鎖および/または配列番号14のアミノ酸配列を有する軽鎖を含む、上記(1)~(6)のいずれか1項に記載の抗体またはその断片。
(8)上記抗体が、受領番号FERM ABP-10950で特定されるハイブリドーマ細胞によって産生されるモノクローナル抗体である、上記(6)に記載の抗体またはその断片。
(9)上記抗体が、キメラ抗体、ヒト化抗体、又は、ヒト抗体である、上記(1)~(7)のいずれか1項に記載の抗体またはその断片。
(10)上記抗体断片が、F(ab’)2、Fab’、Fab、一本鎖Fv(scFv)、ジスルフィド結合Fv(dsFv)若しくはこれらの重合体、又は、二量体化V領域(Diabody)である、上記(1)~(5)のいずれか1項に記載の抗体またはその断片。
(11)上記抗体の断片が、抗体のCDR配列を含むペプチドである、上記(1)~(5)のいずれか1項に記載の抗体またはその断片。
(12)上記CDR配列が、配列番号15、配列番号16、配列番号17、配列番号18、配列番号19、または配列番号20のアミノ酸配列を有する、上記(11)に記載の抗体またはその断片。
(13)上記(1)~(12)のいずれか1項に記載の抗体またはその断片をコードするDNA。
(14)上記(13)に記載のDNAを含有する組み換えベクター。
(15)上記(14)に記載の組み換えベクターを宿主細胞に導入して得られる形質転換細胞。
(16)ハイブリドーマ細胞系である、上記(15)に記載の細胞。
(17)受領番号FERM ABP-10950で特定されるハイブリドーマ細胞系である、上記(16)に記載の細胞。
(18)上記(15)又は(16)に記載の細胞を培養し、培養物中で抗体またはその断片を生成させ、培養物から抗体またはその断片を抽出することを特徴とする、上記(1)~(12)のいずれか1項に記載の抗体またはその断片の製造方法。
(19)上記(1)~(12)のいずれか1項に記載の抗体またはその断片を有効成分として含有する、医薬組成物。
(20)細胞増殖、細胞遊走、細胞間接着、又は、血管新生に起因する疾患の治療薬又は予防薬である、上記(19)に記載の医薬組成物。
(21)抗癌剤又は癌転移抑制剤である、上記(19)に記載の医薬組成物。
(22)上記(1)~(12)のいずれか1項に記載の抗体またはその断片を備える診断薬。
(23)細胞増殖、細胞遊走、細胞間接着、又は、血管新生に起因する疾患の診断薬である、上記(22)に記載の診断薬。
本発明の抗体は、例えば、ADAM-15、又は、ADAM-15の一部を有するペプチドを、必要に応じて免疫賦活剤(例えば、鉱油若しくはアルミニウム沈殿物と加熱死菌若しくはリポ多糖体、フロインドの完全アジュバント、または、フロインドの不完全アジュバント等)とともに、非ヒト哺乳動物または鳥類に免疫することにより作製することができる。
例えば、PEG法の場合、上述の方法に従って得られた抗体産生細胞及び骨髄腫細胞を、培地、PBS(Phosphate Buffered Saline)等で洗浄後、30~60%のPEG(平均分子量1000~6000)等の細胞凝集性媒体を含む適当な培地または緩衝液中で、脾細胞と骨髄腫細胞を1:2~10:1(好ましくは、5:1~10:1)の混合比で懸濁し、温度約25~37℃、pH6~8の条件下で、約30秒~3分間程度反応させる(Elsevier Publishing, 1988)。反応終了後、PEG溶液を除いて培地に再懸濁し、セルウェルプレート中に播種して培養を続ける。
培養後、培養上清を採取し、ELISA等により、抗原タンパク質に結合し、非抗原タンパク質に結合しないサンプルを選択する。例えば、「新臨床免疫実験操作法」(part 3)(科学評論社、1997)に記載された細胞ELISA法を用いて確認及びスクリーニングを行うことができる。このようなクローンから限界希釈法を1から5回、好適には2から4回繰り返すことにより単一細胞化を行い、安定して高い抗体価を示す細胞を選択することができる。
(1)ヒト型キメラ抗体
本発明のヒト型キメラ抗体は、ADAM-15と結合し、ADAM-15の機能を阻害する非ヒト動物由来モノクローナル抗体のVH及びVLをコードするDNAを調製し、これをヒト由来免疫グロブリンの定常領域cDNAと結合して発現ベクターに組み込み、適当な宿主細胞に当該ベクターを導入して発現させることにより得ることができる(Morrison, S.L.ら, Proc. Natl. Acad. Sci. USA, 81, 6851-6855, 1984)。
本発明のヒト化抗体は、ADAM-15と結合し、ADAM-15の活性を阻害する非ヒト動物由来モノクローナル抗体のVH及びVLのCDRをコードするアミノ酸配列をヒト抗体のVH及びVLのフレームワーク領域(FR)に移植したV領域をコードするDNAを構築し、構築したDNAをヒト由来免疫グロブリンの定常領域cDNAと結合して発現ベクターに組み込み、適当な宿主細胞に当該ベクターを導入して発現させることにより得ることができる(L. Rieohmannら, Nature, 332, 323, 1988; Kettleborough, C. A.ら, Protein Eng., 4, 773-783, 1991; Clark M., Immunol. Today., 21, 397-402, 2000参照)。
ヒト抗体は、例えば、ヒト抗体ファージライブラリーまたはヒト抗体産生トランスジェニックマウスを利用することにより得ることができる(富塚ら, Nature Genet., 15, 146-156(1997))。
本発明の抗体の断片(F(ab’)2、Fab’、Fab、scFv、dsFv若しくはこれらの重合体、Diabody、または、CDRを含むペプチド)は、以下の方法により作製することができる。
本発明のADAM-15に結合する抗体等は、上述の方法により得られた抗体等のうち、所望のエピトープを認識する抗体等を選択することにより得ることができる。また、本発明のADAM-15を認識する抗体等は、上述の抗ADAM-15抗体作製方法において、抗原として所望のエピトープ配列(好ましくは、ディスインテグリンドメイン配列)を有するペプチドを投与することにより得ることができる。
ADAM-15のディスインテグリンドメインを認識し、かつ、ADAM-15のディスインテグリンドメイン内のループ領域を認識しない抗体等は、前記方法により得られたDAM-15のディスインテグリンドメインを認識する抗体等の中から、ADAM-15のディスインテグリンドメイン内のループ領域を認識しない抗体等を当業者に周知の方法により選択することにより得ることができる。例えば、ADAM-15のディスインテグリンドメインを認識し、かつ、ADAM-15のディスインテグリンドメイン内のループ領域を認識しない抗体等は、ADAM-15を構成するアミノ酸のうち、ADAM-15のディスインテグリンドメイン内のループ領域の少なくとも1アミノ酸にアラニンミューテーションを導入した全長ADAM-15変異体またはADAM-15変異体断片を作製して、当該変異体等と得られた抗体等との結合活性を測定し、全長ADAM-15またはADAM-15断片との結合活性と比較して、結合活性が変化しない抗体等を選択することにより得ることができる。
得られた抗体がADAM-15及びインテグリンαvβ3依存性細胞接着を阻害するか否かは、例えば、得られた抗体の存在下/非存在下における、ADAM-15リコンビナントタンパク質を固相化したプレートへの、インテグリンαvβ3発現細胞の結合を比較することにより調べることができる。コントロールとして抗インテグリンαvβ3抗体の存在下/非存在下における、ADAM-15リコンビナントタンパク質を固相化したプレートへの、インテグリンαvβ3発現細胞の結合を測定することにより、測定している細胞接着が、インテグリンαvβ3依存性細胞接着であるか否かを知ることができる。
得られた抗体がADAM-15及びインテグリンαvβ3依存性細胞接着を阻害するか否かは、例えば、得られた抗体の存在下/非存在下における、ADAM-15リコンビナントタンパク質を固相化したプレートへの、インテグリンα9β1発現細胞の結合を比較することにより調べることができる。コントロールとして抗インテグリンα9β1抗体の存在下/非存在下における、ADAM-15リコンビナントタンパク質を固相化したプレートへの、インテグリンα9β1発現細胞の結合を測定することにより、測定している細胞接着が、インテグリンα9β1依存性細胞接着であるか否かを知ることができる。
得られた抗体等は、ADAM-15とインテグリンとの結合を阻害することにより、情報の細胞内シグナル伝達を遮断できることから、このようなシグナルが関与する疾患の治療薬として使用することができる。ADAM-15とインテグリンを発現している細胞や癌細胞を用い、得られた抗体等の存在下での結合阻害をin vitro又はin vivoで観察することにより、本発明の抗体等の対象疾患を見出すことができる。
本発明の抗体等は、ADAM-15を特異的に認識することができるので、被検液中のADAM-15の定量に使用することができる。本発明の抗体等を備える診断薬は、炎症性疾患、例えばリウマチ関節炎、肝炎、気管支喘息、線維症、糖尿病、癌転移、動脈硬化、多発性硬化症、肉芽腫等の診断剤、また臓器移植後の慢性拒絶反応抑制、全身性自己免疫疾患・エリテマトーデス・ぶどう膜炎・ベーチェト病・多発性筋炎・糸状体増殖性腎炎・サルコイドーシス等の自己免疫疾患の診断剤として用いることができる。本発明の診断薬は、抗体分子を用いた公知の方法に基づくことができる。このような方法としては、例えば、ELISA(Catty, Raykundalia, 1989)、ラジオイムノアッセイ(Catty, Murphy, 1989)、免疫組織化学的方法(Heiderら、1993)、イムノメトリック法、または、ウェスタンブロット等を挙げることができる。本発明の診断薬の検体としては、例えば、生検として被験者から採取した組織試料または液体を使用することができる。使用される生検は、ADAM-15の免疫学的測定の対象となるものであれば特に限定はなく、例えば、組織、血液、尿、漿液、髄液、関節液、眼房水、涙液、唾液またはそれらの分画物若しくは処理物を挙げることができる。本発明の診断薬による分析は、定性的、定量的または半定量的に行うことができる。
ヒトα9インテグリン遺伝子はG361細胞から抽出したトータルRNAから、ReverTraAce (TOYOBO)を用いて合成したcDNAを鋳型としてPCRを行うことでクローニングした。ヒトα9インテグリン遺伝子のクローニングは5’側断片と3’側断片に分割して、以下のプライマーを用いて行った。
ヒトα9インテグリン遺伝子5’側断片
センスプライマー:5’-TTTTAAGCTTGCCACCATGGGCGGCCCGGCTG-3’(配列番号1)
アンチセンスプライマー:5’-AAACTGCAGTCCGGAGCACTGGATTTATCTTCT-3’(配列番号2)
ヒトα9インテグリン遺伝子3’側断片
センスプライマー:5’-AAATCCGGATGTTTGGTCCATATC-3’(配列番号3)
アンチセンスプライマー:5’-AAATCTAGATCACTGGTTTTTCTGGACCCAGTC-3’(配列番号4)
ヒトADAM-15ディスインテグリンドメインのDNA鎖をPCR法で複製した。HUVECのcDNA 1μLを鋳型とし、それぞれ0.5μLの100μMセンスプライマーと100μMアンチセンスプライマー、8μLの2.5mM dNTP mix、0.5μLのEX-Tagポリメラーゼ(2.5U/100μL: Takara)、10μLの10×PCRバッファー、を79.5μLの超純水に加え、PCR反応液を調整した。サーマルサイクラーを用いて、94℃で5分を1サイクル、94℃で1分、55℃で1分、72℃で1分を35サイクル、72℃で5分を1サイクルでPCR反応を行なった。使用したプライマーは以下のとおりである。
センスプライマー:5’-CCTATGGCTGCTTTCTGC-3’(配列番号5)
アンチセンスプライマー:5’-CATGCACACAGCTTGCCC-3’(配列番号6)
センスプライマー:5’-AAGGATCCGCTGCTTTCTGCGGA-3’(配列番号7)
アンチセンスプライマー:5’-ATTCTCGAGATCCCCTAGGCTGACAT-3’(配列番号8)
実施例2で作製した、ヒトADAM-15ディスインテグリンドメイン/ pGEX-6P-1をJM-109に形質転換し、アンピシリン(SIGMA-Ardrich)を添加したLB培地で増殖させ、対数増殖期に200μM IPTG(Amersham Bioscience)を添加することでGST融合タンパク質の発現を誘導した。大腸菌を回収後、NETN-150バッファー(50mM Tris pH7.2, 1mM EDTA, 150mM NaCl, 0.5% NP-40)に懸濁し、ソニケーションをかけることでタンパク質を抽出した。遠心後、その上清をグルタチオンセファロースビーズ4B(Amersham Bioscience)に添加し、4℃で2時間転倒混和した。ビーズをNETN-100バッファー(50mM Tris pH7.2, 1mM EDTA, 100mM NaCl, 0.5%NP-40)で洗浄し、還元型グルタチオン溶液(100mM Tris pH8.8, 20mM Reduced Glutathione(Wako))で溶出し、これをGST融合タンパク質とした。また、GSTを切断したタンパク質を作製する際には、大腸菌で発現させたタンパク質をグルタチオンセファロースビーズに吸着させるまでは同様の方法で行い、ビーズをNETN-100バッファーで洗浄した後に、prescission protease(Amersham Bioscience) を用いて酵素処理することでGSTを切断した。
ヒトADAM-15ディスインテグリンドメインにおけるRGD配列をRAA配列に置換したタンパク質(以下、「ヒトADAM-15ディスインテグリンドメインタンパク質(RAA置換体)」という)は、次の方法により作製した。実施例2で作製した、ヒトADAM-15ディスインテグリンドメイン/ pGEX-6P-1を鋳型としてそれぞれ1.25μLの、100μg/mlのセンスプライマーと100μg/mlのアンチセンスプライマー、1μLの2.5mM dNTP mix、1μLのpfu turboポリメラーゼ(2.5U/μL)、5μLの10×PCRバッファーを、40.4μLの超純水に加え、PCR反応液を調整した。サーマルサイクラーを用いて、95℃で30秒を1サイクル、95℃で30秒、55℃で1分、68℃で5分30秒を18サイクル、72℃で7分を1サイクルでPCR反応を行なった。使用したプライマーは以下のとおりである。
センスプライマー:5’-CAGTGTCCTACCAGAGCTGCTTGTGACTTGCCTG-3’(配列番号9)
アンチセンスプライマー:5’-CAGGCAAGTCACAAGCAGCTCTGGTAGGACGACACTG-3(配列番号10)
実施例3で作製した、ヒトADAM-15ディスインテグリンドメイン-GSTタンパク質をBALB/cマウス(メス、7週令: SAMKYO LABO SERVICE CORPORATION)に計4回免疫した。初回は100μgのタンパク質を完全フロイントアジュバンド(SIGMA)で乳化して、以降は50μgのタンパク質を不完全フロイントアジュバンド(SIGMA)で乳化して、マウスに免疫した。4回免疫後、マウスから採血し、その血清を用いて抗体価測定をELISAにより行った。その後、50μgのタンパク質をPBSに溶解し、追加免疫した。
(実施例6)抗ADAM-15モノクローナル抗体23G9と8F7の結合活性比較
GSTを除去したヒトADAM-15ディスインテグリンドメインリコンビナントタンパク質、又は、ヒトADAM-15ディスインテグリンドメインタンパク質(RAA置換体)を、PBSで0~5μg/mLに調製し、96ウェルプレートの各ウェルに50μLずつ添加し、37℃で1時間インキュベートして、固相化させた。その後、0.5%BSA/PBSを各ウェルに200μLずつ添加し、室温で1時間インキュベートすることでブロッキング反応を行なった。PBSで洗浄後、実施例1で作製したhα9/CHO細胞、又は、非遺伝子導入CHO-K1細胞を0.25%BSA含有培地(D-MEM Ham’sF-12)で1×105cells/mlに調製して、各ウェルに200μLずつ添加し、37℃で1時間インキュベートして固相に固定化させたタンパク質に接着させた。その後、あらかじめ37℃に温めておいたPBSで洗浄して、接着していない細胞を除去した。クリスタルバイオレットを各ウェルに50μLずつ添加し、室温で30分間インキュベートすることで、細胞を固定、染色した。水道水で洗浄後、20%酢酸水を各ウェルに100μLずつ添加し、細胞を溶解後、プレートリーダーで590nmの吸光度を測定した。
ヒト腎癌細胞株NRC-12細胞を用いて、8F7のRGD非依存的な接着を抑制できるかを検討するために、NRC-12細胞におけるintegrinの発現をフローサイトメトリーで確認した。0.5%BSA、0.01NaN3/PBS(FACSバッファー)で細胞を5×106/mlに調整し、96穴V底プレートの各ウェルに100mlずつ添加し、プレート遠心機で細胞を回収した。その後、CFBSを各ウェルに100mlずつ添加し、氷上で30分間インキュベートすることで、細胞膜表面上のFcレセプターをブロッキングした。一次抗体を0.5μg添加し、氷上で20分間インキュベートした。FACSバッファーで2回洗浄後、200倍希釈した二次抗体(anti-mouse IgG FITC標識:Jackson immunoresearch)を各ウェルに100μLずつ添加し、氷上で20分間インキュベートした。FACSバッファーで2回洗浄後、7-AAD(50μg/ml)を各ウェルに20μLずつ添加し、氷上で20分間インキュベートした。FACSバッファーで3回洗浄後、細胞をメッシュに通し、最終的に500μLのFACSバッファーに溶解した。その後、FACSキャリバー(日本ベクトン・ディッキンソン)用いて、FL-1を検出し、cell questで解析した。
(実施例9)ヒト腎癌細胞株NRC-12細胞を用いた細胞接着及び細胞接着阻害試験
実施例6と同様の方法により、ヒト腎癌細胞株NRC-12細胞の、d.d.、固相化したd.d.と合成ペプチド(GRGDS)の混合物(d.d.+GRGDS)、d.d.と合成ペプチド(GRGES)の混合物(d.d.+GRGES)、合成ペプチド(GRGDS)をBSA(牛血清アルブミン)と結合させたもの(GRGDS-BSA)、合成ペプチド(GRGDS)をBSA(牛血清アルブミン)と結合させたものと合成ペプチド(GRGDS)の混合物(GRGDS-BSA+GRGDS)、又は、合成ペプチド(GRGDS)をBSA(牛血清アルブミン)と結合させたもの合成ペプチド(GRGES)の混合物(GRGDS-BSA+GRGES)への細胞接着活性を測定した。また、実施例6と同様の方法により、ヒト腎癌細胞株NRC-12細胞の、d.d固相化表面への細胞接着に対する、8F7の阻害活性を測定した。
ヒト乳癌細胞株435S(MDA-MB-435S)におけるADAM-15とintegrinの発現をフローサイトメトリーで確認した。フローサイトメトリーは、実施例7に記載の方法に準じて行った。
ヒト乳癌細胞株435Sでのインテグリンの発現が確認できたため、これらのインテグリンが機能的であるかどうかを細胞接着試験により検討した。即ち、d.d.又はd.d.-RAAに対する435Sの細胞接着を以下の方法により測定した。d.d、d.d.-RAA、ヒトテネーシンC分子内に存在する3番目のフィブロネクチンtypeIIIドメインのリコンビナント蛋白(hTNfn3)のRGD配列をRAAに置換した蛋白(hTNfn3(RAA))、又は、GRGDS-BSAを、PBSで0~5μg/mLに調製し、96ウェルプレートの各ウェルに50μLずつ添加し、37℃で1時間インキュベートして、固相化させた。その後、0.5%BSA/PBSを各ウェルに200μLずつ添加し、室温で1時間インキュベートすることでブロッキング反応を行なった。PBSで洗浄後、ヒト乳癌細胞株435S細胞を0.25%BSA含有培地(TIL)で1×105cells/mlに調製して、各ウェルに200μLずつ添加し、37℃で1時間インキュベートして固相化させたタンパク質に接着させた。その後、あらかじめ37℃に温めておいたPBSで洗浄して、接着していない細胞を除去した。クリスタルバイオレットを各ウェルに50μLずつ添加し、室温で30分間インキュベートすることで、細胞を固定、染色した。水道水で洗浄後、20%酢酸水を各ウェルに100μLずつ添加し、細胞を溶解後、プレートリーダーで590nmの吸光度を測定した。
ヒト乳癌細胞株435S細胞を用いた細胞接着阻害試験においては、Mnイオンを用いることにより、インテグリンを活性化させた。細胞接着試験と同様の方法でd.d、又は、d.d.-RAA(6.25μg/mlに調製)を固相化させ、ブロッキング反応を行なった。ADAM-15を阻害することによる細胞接着阻害活性試験においては、固相に固定したタンパク質に8F7を添加した。また、インテグリンを阻害することによる細胞接着阻害活性試験においては、ヒト乳癌細胞株435S細胞2×104細胞に、ヒトα9β1インテグリンに対する抗体であるY9A2(chemicon)、又は、ヒトαvβ3インテグリンに対する抗体であるLM-609(chemicon)を添加し、37℃で20分間インキュベートした。その後、細胞接着試験と同様の方法で細胞を各ウェルに添加して細胞接着を測定した。
ヒト乳癌細胞株435S細胞(MDA-MB-435S:435S)を10% FCS含有TIL培地で2×104 / mlに調整し、96ウェルプレートの各ウェルに100μLずつまき、37℃で一晩培養した後、FCS不含TIL培地に交換し、同様に一晩培養した。培地を除去し、5%FCS含有TIL培地で20μg/mlに調整した抗体(実施例5で作製した8F7、又は、抗ヒトαvβ3インテグリン抗体LM-609(chemicon))を各ウェルに100μLずつ添加し、cell counting kit-8(DOUJINDO)を各ウェルに10μLずつ添加した。37℃で2時間30分インキュベートした後にプレートリーダーで450nmの吸光度を測定した。これを0時間とし、抗体を含む5%FCS含有TIL培地で48時間培養した細胞においても、同様の方法で実験を行った。450nm(48時間)/450nm(0時間)の割合を算出し、これらの割合を抗体非添加群と比較した。
本明細書に記載の実施例において、ELISA法は、次の方法により行った。まず、抗原を96ウェルプレートに添加し、4℃で一晩固相化させた。その後、PBSで3回洗浄し、1%BSA、0.05% NaN3/PBSを200ml/wellで添加することでブロッキング反応を行った。0.05%Tween/PBSで5回洗浄後、1% BSA、0.05% Tween/PBSで希釈した一次抗体を各ウェルに100μLずつ添加し、37℃で1時間反応させた。0.05%Tween/PBSで7回洗浄後、1% BSA、0.05% Tween/PBSで1000倍希釈した二次抗体(anti-mouse IgG HRP標識: Jackson immunoresearch)を50ml/wellで添加し、37℃で30分反応させた。0.05%Tween/PBSで9回洗浄後、o-フェニレンジアミン溶液(Wako)を50ml/wellで添加し、室温、暗所で15分反応させた。2N硫酸で反応停止後、プレートリーダーを用いてOD490の吸光度を測定した。
本明細書における細胞接着阻害試験においては、抗体非添加群のOD590を基準とし、抗体添加群で得られたOD590の割合を算出した。細胞増殖試験においては、各々で48時間後 / 0時間の値を算出し、抗体非添加群で得られた割合を基準にし、抗体添加群の割合を算出した。これらの実験はすべて3回ずつ行い、スチューデントのt検定を行った。
8F7の細胞浸潤に及ぼす影響を調べるために細胞浸潤試験を行った。細胞浸潤試験はマトリゲルインベージョンチャンバー(BD社)を用いて行った。無血清のTIL培地(免疫生物研究所社)をウェルとインサートに500mlずつ添加し、インサートをウェルに浸した。37℃で2時間インキュベーションすることで、マトリゲルを水和した。その後、インサート内の培地を吸引除去し、化学誘因物質を750ml添加した別のウェルに浸した。化学誘因物質はヒト繊維芽肉腫細胞株HT-1080細胞株の培養上清を用いた。無血清のTIL培地で1×105個/mlに調整した435S細胞懸濁液をインサートに500ml添加し、37℃で22時間インキュベーションすることで浸潤を誘導した。抗体による細胞浸潤の阻害効果を調べる場合は、乳癌細胞をインサートに添加する前に、8F7抗体またはコントロール抗体を10mg/mlになるように添加し、37℃で20分インキュベーションし、435S細胞懸濁液をインサートに添加した。浸潤後に、インサート内の細胞懸濁液を吸引除去し、綿棒でマトリゲルと非浸潤細胞を拭き取った。その後、冷却したメタノールにインサートを浸し、-80℃で20分インキュベーションすることで、浸潤細胞を固定した。固定後、ギムザ溶液(武藤化学株式会社)にインサートを15分浸し、浸潤細胞を染色した。水道水で洗浄後、インサートからフィルターを取り外し、スライド上に置き、マウント剤にて封入した。光学顕微鏡でフィルター下層の浸潤面を観察し、核が観察できる細胞を浸潤細胞として計数した。なお、6視野を計数し、その平均値を算出した。
ハイブリドーマ細胞を、illustra Quickprep Micro mRNAPurification Kit(GEヘルスケアバイオサインス社)を用いてRNAを抽出し、SuprScriptFirst-strand cDNA for RT-PCRキット(インビトロジェン社)にてcDNAを作製した。Heavy primer増幅キット(アマシャムバイオサイエンス社)およびLightprimer増幅キット(アマシャムバイオサイエンス社)を用いてPCRを行い、抗体の重鎖(Heavy chain)および抗体の軽鎖(Lightchain)cDNAを伸張させ、重鎖のPCR産物をpTAベクター(東洋紡績社)へ、そして軽鎖のPCR産物をMighty Cloning Kit <Blunt End>(タカラバイオ社)組み込み、cDNA配列、アミノ酸配列を決定した。CDR領域は、Kabat numbering systemを利用して決定した。
[CDRH1]
SYNMH(配列番号15)
[CDRH2]
AIYPGDGDTSYNQKFKG(配列番号16)
[CDRH3]
DRGDYGYGFAY(配列番号17)
(軽鎖)
[CDRL1]
RSSQSLVHSNGNTYLH(配列番号18)
[CDRL2]
KVSNRFS(配列番号19)
[CDRL3]
SQNTHVPPWT(配列番号20)
Claims (23)
- ADAM-15のディスインテグリンドメインを認識し、かつ、ADAM-15のディスインテグリンドメイン内のRGD配列を認識しない抗体またはその断片。
- ADAM-15のディスインテグリンドメインドメインを認識し、かつ、ADAM-15のディスインテグリンドメイン内のループ領域を認識しない抗体またはその断片。
- 請求項1又は請求項2に記載の抗体またはその断片であって、ADAM-15及びインテグリンαvβ3依存性細胞接着を阻害する抗体またはその断片。
- 請求項1~請求項3のいずれか1項に記載の抗体またはその断片であって、ADAM-15及びインテグリンα9β1依存性細胞接着を阻害する抗体またはその断片。
- 請求項1~請求項4のいずれか1項に記載の抗体またはその断片であって、癌細胞の増殖を抑制することを特徴とする抗体またはその断片。
- 前記抗体が、モノクローナル抗体である、請求項1~請求項5のいずれか1項に記載の抗体またはその断片。
- 前記抗体が、配列番号12のアミノ酸配列を有する重鎖および/または配列番号14のアミノ酸配列を有する軽鎖を含む、請求項1~6のいずれか1項に記載の抗体またはその断片。
- 前記抗体が、受託番号FERM BP-10950で特定されるハイブリドーマ細胞によって産生されるモノクローナル抗体である、請求項6に記載の抗体またはその断片。
- 前記抗体が、キメラ抗体、ヒト化抗体、又は、ヒト抗体である、請求項1~請求項7のいずれか1項に記載の抗体またはその断片。
- 前記抗体断片が、F(ab’)2、Fab’、Fab、一本鎖Fv(scFv)、ジスルフィド結合Fv(dsFv)若しくはこれらの重合体、又は、二量体化V領域(Diabody)である、請求項1~請求項5のいずれか1項に記載の抗体またはその断片。
- 前記抗体の断片が、抗体のCDR配列を含むペプチドである、請求項1~請求項5のいずれか1項に記載の抗体またはその断片。
- 前記CDR配列が、配列番号15、配列番号16、配列番号17、配列番号18、配列番号19、または配列番号20のアミノ酸配列を有する、請求項11に記載の抗体またはその断片。
- 請求項1~請求項12のいずれか1項に記載の抗体またはその断片をコードするDNA。
- 請求項13に記載のDNAを含有する組み換えベクター。
- 請求項14に記載の組み換えベクターを宿主細胞に導入して得られる形質転換細胞。
- ハイブリドーマ細胞系である、請求項15に記載の細胞。
- 受託番号FERM BP-10950で特定されるハイブリドーマ細胞系である、請求項16に記載の細胞。
- 請求項15又は請求項16に記載の細胞を培養し、培養物中で抗体またはその断片を生成させ、培養物から抗体またはその断片を抽出することを特徴とする、請求項1~請求項12のいずれか1項に記載の抗体またはその断片の製造方法。
- 請求項1~請求項12のいずれか1項に記載の抗体またはその断片を有効成分として含有する、医薬組成物。
- 細胞増殖、細胞遊走、細胞浸潤、細胞間接着、又は、血管新生に起因する疾患の治療薬又は予防薬である、請求項19に記載の医薬組成物。
- 抗癌剤又は癌転移抑制剤である、請求項19に記載の医薬組成物。
- 請求項1~請求項12のいずれか1項に記載の抗体またはその断片を備える診断薬。
- 細胞増殖、細胞遊走、細胞浸潤、細胞間接着、又は、血管新生に起因する疾患の診断薬である、請求項22に記載の診断薬。
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009553435A JP5526407B2 (ja) | 2008-02-14 | 2009-02-12 | 抗adam−15抗体及びその利用 |
US12/867,449 US8461310B2 (en) | 2008-02-14 | 2009-02-12 | Anti-ADAM-15 antibodies and utilization of the same |
AU2009213453A AU2009213453B2 (en) | 2008-02-14 | 2009-02-12 | Anti-ADAM-15 antibodies and utilization of the same |
EP09710825.2A EP2246430B1 (en) | 2008-02-14 | 2009-02-12 | Anti-adam-15 antibodies and utilization of the same |
CA2714657A CA2714657C (en) | 2008-02-14 | 2009-02-12 | Anti-adam-15 antibodies and utilization of the same |
CN200980105234XA CN101946003B (zh) | 2008-02-14 | 2009-02-12 | 抗adam-15抗体及其应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008033354 | 2008-02-14 | ||
JP2008-033354 | 2008-02-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009101968A1 true WO2009101968A1 (ja) | 2009-08-20 |
Family
ID=40956998
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/052290 WO2009101968A1 (ja) | 2008-02-14 | 2009-02-12 | 抗adam-15抗体及びその利用 |
Country Status (8)
Country | Link |
---|---|
US (1) | US8461310B2 (ja) |
EP (1) | EP2246430B1 (ja) |
JP (1) | JP5526407B2 (ja) |
KR (1) | KR101604877B1 (ja) |
CN (1) | CN101946003B (ja) |
AU (1) | AU2009213453B2 (ja) |
CA (1) | CA2714657C (ja) |
WO (1) | WO2009101968A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012042391A3 (en) * | 2010-10-01 | 2012-08-23 | Salman Rahman | Methods for the development of metzincin-selective catalytic cleft directed antibodies for therapeutic and diagnostic applications |
CN103937770A (zh) * | 2013-01-18 | 2014-07-23 | 北京义翘神州生物技术有限公司 | 一种重组表达的ADAM15h融合蛋白及其制备方法与应用 |
JP2015504659A (ja) * | 2011-12-15 | 2015-02-16 | アムジエン・インコーポレーテツド | 凝集方法 |
US9040049B2 (en) | 2008-03-24 | 2015-05-26 | Vasgen Limited | ADAM-15 antibodies and immunogenic peptides |
WO2015152413A1 (ja) * | 2014-04-03 | 2015-10-08 | 地方独立行政法人東京都健康長寿医療センター | 加齢または筋萎縮の診断用バイオマーカー |
US9504720B2 (en) | 2011-02-02 | 2016-11-29 | Asahi Group Holdings, Ltd. | Substance for preventing and improving arthritis |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0125023A1 (en) | 1983-04-08 | 1984-11-14 | Genentech, Inc. | Recombinant immunoglobulin preparations, methods for their preparation, DNA sequences, expression vectors and recombinant host cells therefor |
EP0546073A1 (en) | 1990-08-29 | 1993-06-16 | Genpharm Int | NON-HUMAN TRANSGENETES CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES. |
US5830742A (en) | 1995-06-08 | 1998-11-03 | Immunex Corporation | TNF-α converting enzyme |
JP2003523768A (ja) * | 2000-02-25 | 2003-08-12 | イミュネックス・コーポレーション | インテグリンアンタゴニスト |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003270625A1 (en) * | 2002-09-11 | 2004-04-30 | Justus-Liebig-Universität Giessen | Inhibition or activation of adam9 and adam15 for treatment of vascularization-related disease and wound healing |
-
2009
- 2009-02-12 WO PCT/JP2009/052290 patent/WO2009101968A1/ja active Application Filing
- 2009-02-12 CA CA2714657A patent/CA2714657C/en not_active Expired - Fee Related
- 2009-02-12 AU AU2009213453A patent/AU2009213453B2/en not_active Ceased
- 2009-02-12 CN CN200980105234XA patent/CN101946003B/zh not_active Expired - Fee Related
- 2009-02-12 US US12/867,449 patent/US8461310B2/en not_active Expired - Fee Related
- 2009-02-12 JP JP2009553435A patent/JP5526407B2/ja not_active Expired - Fee Related
- 2009-02-12 EP EP09710825.2A patent/EP2246430B1/en not_active Not-in-force
- 2009-02-12 KR KR1020107019821A patent/KR101604877B1/ko active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0125023A1 (en) | 1983-04-08 | 1984-11-14 | Genentech, Inc. | Recombinant immunoglobulin preparations, methods for their preparation, DNA sequences, expression vectors and recombinant host cells therefor |
EP0546073A1 (en) | 1990-08-29 | 1993-06-16 | Genpharm Int | NON-HUMAN TRANSGENETES CAPABLE OF PRODUCING HETEROLOGICAL ANTIBODIES. |
US5830742A (en) | 1995-06-08 | 1998-11-03 | Immunex Corporation | TNF-α converting enzyme |
US6013466A (en) | 1995-06-08 | 2000-01-11 | Immunex Corporation | TNF-α converting enzyme |
JP2003523768A (ja) * | 2000-02-25 | 2003-08-12 | イミュネックス・コーポレーション | インテグリンアンタゴニスト |
Non-Patent Citations (38)
Title |
---|
ALFANDARI, D. ET AL., DEV.BIOL., vol. 182, 1997, pages 314 - 330 |
ALMEIDA, E.A. ET AL., CELL, vol. 81, 1995, pages 1095 - 1104 |
CHARRIER, L. ET AL., J BIOL CHEM, vol. 282, 2007, pages 16948 - 16958 |
CHIRGWIN, J. M. ET AL., BIOCHEMISTRY, vol. 18, 1979, pages 5294 - 5299 |
CHOMCZYNSKI, P ET AL., ANALYTICAL BIOCHEMISTRY, vol. 162, 1987, pages 156 - 159 |
CHOTHIA; LESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917 |
CLARK M., IMMUNOL. TODAY., vol. 21, 2000, pages 397 - 402 |
CURR. TOP. MICROBIOL. IMMUNOL., vol. 81, 1978, pages 1 |
ETO, K ET AL.: "RGD-independent binding of integrin alpha9betal to the ADAM-12 and -15 disintegrin domains mediate cell-cell interaction", J BIOL. CHEM., vol. 275, 2000, pages 34922 - 34930 |
ETO, K. ET AL., J. BIOL. CHEM., vol. 277, 2002, pages 17804 - 17810 |
ETO, K.; HUET, C.; TARUI, T.; KUPRIYANOV, S.; LIU, H. Z.; PUZON-MCLAUGHLIN, W.; ZHANG, X. P.; SHEPPARD, D.; ENGVALL, E.; TAKADA, Y: "Functional classification of ADAMs based on a conserved motif for binding to integrin alpha 9beta 1: implications for sperm-egg binding and other cell interactions", J BIOL CHEM, vol. 277, 2002, pages 17804 - 17810 |
ETO,K. ET AL.: "Functional classification of ADAMs based on a conserved motif for binding to integrin alpha 9beta 1: implications for sperm- egg binding and other cell interactions", J BIOL CHEM, vol. 277, no. 20, 2002, pages 17804 - 10, XP008139837 * |
EUR. J. IMMUNOL., vol. 6, 1976, pages 292 |
GALFRE, G.; MILSTEIN, C., METHODS ENZYMOL., vol. 73, 1981, pages 3 - 46 |
HAM, C. ET AL., EXP CELL RES, vol. 279, 2002, pages 239 - 247 |
HERREN, B. ET AL., EXP CELL RES, vol. 271, 2001, pages 152 - 160 |
HORIUCHI, K. ET AL., MOL CELL BIOL, vol. 23, 2003, pages 5614 - 5624 |
J. IMMUNOL. METHODS, vol. 35, 1980, pages 1 |
J. IMMUNOL., vol. 123, 1979, pages 1548 |
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1983, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES |
KETTLEBOROUGH, C. A. ET AL., PROTEIN ENG., vol. 4, 1991, pages 773 - 783 |
KOMIYA, K. ET AL., ARTHRITIS RES THER, vol. 7, 2005, pages 158 - 1173 |
L. RIEOHMANN ET AL., NATURE, vol. 332, 1988, pages 323 |
MARTIN,J. ET AL.: "The role of ADAM 15 in glomerular mesangial cell migration", J BIOL CHEM, vol. 277, no. 37, 2002, pages 33683 - 9, XP002557693 * |
MORRISON, S.L. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 6851 - 6855 |
NATH, D. ET AL., J. CELL SCI., vol. 112, 1999, pages 579 - 587,468-473 |
NATURE, vol. 256, 1975, pages 495 |
NATURE, vol. 276, 1978, pages 269 |
R. C. MULLIGAN; P. BERG, SCIENCE, vol. 209, 1980, pages 1422 |
R. ORLANDI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 3833 |
SCHUTZ,A. ET AL.: "Expression of ADAM15 in lung carcinomas", VIRCHOWS ARCH, vol. 446, no. 4, 2005, pages 421 - 9, XP019344709 * |
See also references of EP2246430A4 |
TOMIZUKA ET AL., NATURE GENET., vol. 15, 1997, pages 146 - 156 |
TORTORELLA, M. D. ET AL., SCIENCE, vol. 284, 1999, pages 1664 - 1666 |
TROCHON-JOSEPH, V. ET AL., CANCER RES, vol. 64, 2004, pages 2062 - 2069 |
WEN, C. ET AL., DEVELOPMENT, vol. 124, 1997, pages 4759 - 4767 |
ZHANG, X.P. ET AL., J. BIOL.CHEM., vol. 273, 1998, pages 7345 - 7350 |
ZHANG,X.P. ET AL.: "Specific interaction of the recombinant disintegrin-like domain of MDC-15 (metargidin, ADAM-15) with integrin alphavbeta3", J BIOL CHEM, vol. 273, no. 13, 1998, pages 7345 - 50, XP002201315 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9040049B2 (en) | 2008-03-24 | 2015-05-26 | Vasgen Limited | ADAM-15 antibodies and immunogenic peptides |
JP2013541534A (ja) * | 2010-10-01 | 2013-11-14 | ラーマン,サルマン | 治療および診断用途のためのメトジンシン選択性の触媒クレフト特異的抗体の生成方法 |
US9732157B2 (en) | 2010-10-01 | 2017-08-15 | Salman Rahman | Methods for the development of metzincin-selective catalytic cleft directed antibodies for therapeutic and diagnostic applications |
WO2012042391A3 (en) * | 2010-10-01 | 2012-08-23 | Salman Rahman | Methods for the development of metzincin-selective catalytic cleft directed antibodies for therapeutic and diagnostic applications |
US9504720B2 (en) | 2011-02-02 | 2016-11-29 | Asahi Group Holdings, Ltd. | Substance for preventing and improving arthritis |
JP2015504659A (ja) * | 2011-12-15 | 2015-02-16 | アムジエン・インコーポレーテツド | 凝集方法 |
JP2019022515A (ja) * | 2011-12-15 | 2019-02-14 | アムジエン・インコーポレーテツド | 凝集方法 |
JP2022000046A (ja) * | 2011-12-15 | 2022-01-04 | アムジエン・インコーポレーテツド | 凝集方法 |
JP6998853B2 (ja) | 2011-12-15 | 2022-01-18 | アムジエン・インコーポレーテツド | 凝集方法 |
JP7274547B2 (ja) | 2011-12-15 | 2023-05-16 | アムジエン・インコーポレーテツド | 凝集方法 |
CN103937770A (zh) * | 2013-01-18 | 2014-07-23 | 北京义翘神州生物技术有限公司 | 一种重组表达的ADAM15h融合蛋白及其制备方法与应用 |
WO2015152413A1 (ja) * | 2014-04-03 | 2015-10-08 | 地方独立行政法人東京都健康長寿医療センター | 加齢または筋萎縮の診断用バイオマーカー |
JPWO2015152413A1 (ja) * | 2014-04-03 | 2017-04-13 | 地方独立行政法人東京都健康長寿医療センター | 加齢または筋萎縮の診断用バイオマーカー |
Also Published As
Publication number | Publication date |
---|---|
US8461310B2 (en) | 2013-06-11 |
KR101604877B1 (ko) | 2016-03-18 |
AU2009213453A8 (en) | 2010-09-09 |
EP2246430A1 (en) | 2010-11-03 |
JP5526407B2 (ja) | 2014-06-18 |
KR20100123857A (ko) | 2010-11-25 |
EP2246430B1 (en) | 2013-12-11 |
CA2714657C (en) | 2018-03-27 |
CN101946003B (zh) | 2013-05-15 |
CA2714657A1 (en) | 2009-08-20 |
AU2009213453B2 (en) | 2014-06-19 |
US20100317835A1 (en) | 2010-12-16 |
AU2009213453A1 (en) | 2009-08-20 |
CN101946003A (zh) | 2011-01-12 |
EP2246430A4 (en) | 2011-12-07 |
JPWO2009101968A1 (ja) | 2011-06-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4871740B2 (ja) | 抗α9インテグリン抗体とその用途 | |
AU2007273467B2 (en) | Antihuman alpha9 integrin antibody and use of the same | |
JP5526407B2 (ja) | 抗adam−15抗体及びその利用 | |
US9040295B2 (en) | Anti-human α9 integrin antibody and use thereof | |
JP5306659B2 (ja) | 抗ヒトα9インテグリン抗体とその用途 | |
JPWO2005105144A1 (ja) | 潜在型TGF−βの活性化抑制剤 | |
WO2012101125A1 (en) | Specific antibodies against human cxcl4 and uses thereof | |
JP5687305B2 (ja) | 抗ヒトα9インテグリン抗体とその用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980105234.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09710825 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2714657 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009553435 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12867449 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009710825 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2009213453 Country of ref document: AU Date of ref document: 20090212 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20107019821 Country of ref document: KR Kind code of ref document: A |